← FDA DRUG APPROVALS

FDA ANDA · ANDA040903

IMIPRAMINE HYDROCHLORIDE

Sponsor: LEADING

APPLICATION
ANDA040903
TYPE
ANDA
ORIGINAL APPROVAL
2012-10-24
LATEST ACTION
2025-06-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

IMIPRAMINE HYDROCHLORIDEPrescription
IMIPRAMINE HYDROCHLORIDE 50MG · TABLET · ORAL
IMIPRAMINE HYDROCHLORIDEPrescription
IMIPRAMINE HYDROCHLORIDE 10MG · TABLET · ORAL
IMIPRAMINE HYDROCHLORIDEPrescription
IMIPRAMINE HYDROCHLORIDE 25MG · TABLET · ORAL

Approval history

2025-06-24Labeling · Supplement 11 · standardAP
2023-10-06Labeling · Supplement 8 · standardAP
2014-11-17Labeling · Supplement 4 · standardAP
2012-10-24OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →